Pages that link to "Q35621045"

The following pages link to Cell cycle regulatory functions of the human oncoprotein MDM2. (Q35621045):

Displaying 35 items.

• Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1 (Q24298615) (← links)
• HDM2-binding partners: interaction with translation elongation factor EF1alpha (Q24300548) (← links)
• Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism (Q24681793) (← links)
• Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1 (Q27003153) (← links)
• MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury. (Q30836168) (← links)
• The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. (Q33756262) (← links)
• The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor (Q34030117) (← links)
• A two-step mechanism for cell fate decision by coordination of nuclear and mitochondrial p53 activities. (Q34297075) (← links)
• Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc (Q35082715) (← links)
• Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation (Q35770249) (← links)
• Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds (Q35925277) (← links)
• Splicing up mdm2 for cancer proteome diversity (Q36387622) (← links)
• Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer (Q37059477) (← links)
• Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo (Q37389886) (← links)
• Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. (Q37480094) (← links)
• MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. (Q37635027) (← links)
• Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations (Q37703117) (← links)
• Alterations of p63 and p73 in human cancers (Q38247152) (← links)
• The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing (Q39069982) (← links)
• Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator (Q39074220) (← links)
• In Vivo Anti-Tumor Effect of Expressing p14ARF-TAT Using a FGF2-Targeted Cationic Lipid Vector (Q39605996) (← links)
• Myc and human papillomavirus type 16 E7 genes cooperate to immortalize human keratinocytes (Q40084449) (← links)
• Protecting the genome from mdm2 and mdmx (Q41287206) (← links)
• Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2. (Q41412965) (← links)
• Directing p53 to induce autophagy (Q41870339) (← links)
• The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer (Q41889967) (← links)
• Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells. (Q42200663) (← links)
• Conference report--at the forefront of cancer research: preclinical data highlights of annual meeting of the 95th American Association for Cancer Research; March 27-31, 2004; Orlando, Florida. (Q50746648) (← links)
• Influence of selected anti-cancer drugs on the induction of DNA double-strand breaks and changes in gene expression in human hepatoma HepG2 cells. (Q51332973) (← links)
• Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma (Q58851158) (← links)
• CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer (Q64085173) (← links)
• P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome (Q80727434) (← links)
• Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies (Q87804233) (← links)
• Human Mesenchymal Stem Cells-mediated Transcriptomic Regulation of Leukemic Cells in Delivering Anti-tumorigenic Effects (Q89553356) (← links)
• MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling (Q89807991) (← links)